Skip to main content

Recent News

We've got a new podcast available for download! Dr Jack Cush reviews the news and journal reports and takes cases and questions from rheumatologists. https://t.co/ErJJ5XL8NA #RheumTwitter #RheumNow #medtwitter https://t.co/tqyVNyNYa4
Dr. John Cush @RheumNow (  View Tweet)
Sep 18, 2021
ICYMI: Population study shows risk of H. Zoster in adults to be high among bDMARD and CTX, also increased w/ AZA and HCQ but not MTX SSZ or LEF users. Data from 254065, 1,826311 Pt-Yrs F/U, 6295 new DMARD users, 17024 incident HZ https://t.co/1TeOAWN9LB #RheumNow

Dr. John Cush @RheumNow (  View Tweet)

Sep 18, 2021
ICYMI: Probenecid, an OAT3 inhibitor, has inhibitory effects on RNA viruses (influenza, RSV) & decreases ACE2 expression. May have utility in COVID-19 as it was shown to inhibit SARS-CoV-2 replication in animal models https://t.co/MClSjpqpSa #RheumNow

Dr. John Cush @RheumNow (  View Tweet)

Sep 18, 2021

Serious Infection Risk High in Patients With Lupus

MedPage Today
Sep 17, 2021

Patients with systemic lupus erythematosus (SLE) had two to four times higher risk for serious infection requiring hospitalization, a nationwide Swedish study found.

Read Article
Do More DMARDs Mean More Switching? Tune in to this week's podcast to find out. https://t.co/ErJJ5XL8NA #RheumNow #RheumTwitter #medtwitter https://t.co/5Ufk0XQbmb
Dr. John Cush @RheumNow (  View Tweet)
Sep 17, 2021
Looking for Rx updates? We’ve got them for you. https://t.co/FOfqUvZ8nx

Dr. John Cush @RheumNow (  View Tweet)

Sep 17, 2021
ACR Responds to 2022 Medicare Physician Fee Schedule Proposed Rule Read more: https://t.co/SVGhfhp6Fg #RheumNow #RheumTwitter #medtwitter https://t.co/g46wYCdary
Dr. John Cush @RheumNow (  View Tweet)
Sep 17, 2021
Breakthrough COVID infection. Breakthrough brilliance in a KOL A must read from Len Calabrese https://t.co/2Ljzau5nBG

Dr. John Cush @RheumNow (  View Tweet)

Sep 17, 2021
A retrospective records review of patients with periodic fever syndromes (PFS) receiving IL-1 inhibitor treatment with canakinumab (CAN), shows CAN to be effective and safe in a variety of PFS patients. https://t.co/4lqMhE6ikx #RheumNow #RheumTwitter #medtwitter https://t.co/yThiwJhcwO
Dr. John Cush @RheumNow (  View Tweet)
Sep 17, 2021
32 RA pts; each w/ 2 stool samples >6 mos apart - stool metagenome sequencing stool samples and pt activity assessed. Microbiome most influenced by age, followed by those achieving minimum clinically important improvement https://t.co/unaEOOuP34

Dr. John Cush @RheumNow (  View Tweet)

Sep 17, 2021
Gitelman syndrome (GS) is common salt-wasting genetic tubulopathy causing hypokalaemia and hypomagnesemia. Chondrocalcinosis (CC) is a frequent feature of GS. Study of 57 GS pts - 79% had CC, esp in Cx spine, Knee & wrist. https://t.co/ctEAQq1zzL

Dr. John Cush @RheumNow (  View Tweet)

Sep 17, 2021
Another non stellar result for remdesivir Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): P3, randomised, controlled, open-label trial ⁦@TheLancetInfDis⁩ https://t.co/kNSNj9RM4K

Dr Philip Robinson @philipcrobinson (  View Tweet)

Sep 17, 2021
#ACR21 abstracts now online! NOTE: To coincide with virtual meeting early access, information that goes beyond that contained in the abstract is under embargo until Nov. 1 at 10 AM ET. Browse → https://t.co/o0fpZCHZLC https://t.co/SaNrNQPgau
American College of Rheumatology @ACRheum (  View Tweet)
Sep 17, 2021
#ClinicalPearl Two risks for developing #psoriatic arthritis. Scalp involvement and nail involvement. Yes the patient has PsA https://t.co/sG4DueDtVy
Janet Pope @Janetbirdope (  View Tweet)
Sep 17, 2021

ACR Responds to 2022 Medicare Physician Fee Schedule Proposed Rule

ACR
Sep 16, 2021

In comments submitted to the Centers for Medicare and Medicaid Services (CMS), the American College of Rheumatology (ACR) shared its perspective on the CY 2022 Medicare Physician Fee Schedule and Quality Payment Program proposed rule. 
 

Read Article

Canakinumab Use in Periodic Febrile Disorders

Sep 16, 2021

A retrospective records review of patients with periodic fever syndromes (PFS)  receiving IL-1 inhibitor treatment with canakinumab (CAN), shows CAN to be effective and safe in a variety of PFS patients.

Read Article
American College of OBs & GYNS and the Society for Maternal-Fetal Medicine both enthusiastically endorse COVID Vaccination of pregnant women, given the delta variant, low vax rates in Preg women and poor COVID outcomes in preg. https://t.co/AmP5eOEgr3

Dr. John Cush @RheumNow (  View Tweet)

Sep 16, 2021
Metanalysis of JAK inhibition (tofacitinib & ruxolitinib) in alopecia areata - 12 studies, 346 Pts, Rx success (using SALT50 resp) was 66%, not influenced by age, sex, subtype. Alopecia recurrence seen w/in 3 mos of JAK D/C (in74%) https://t.co/CBSy4Kci80

Dr. John Cush @RheumNow (  View Tweet)

Sep 16, 2021
Popular read— FDA: New Cardiac and Cancer Warnings for All JAK Inhibitors https://t.co/jayl8ufPHn

Dr. John Cush @RheumNow (  View Tweet)

Sep 16, 2021
While following individuals and organizations relevant to you is important, so is following hashtags. Read more… https://t.co/pnRFNQA5BW https://t.co/O2Dpm2r0tx
Dr. John Cush @RheumNow (  View Tweet)
Sep 16, 2021
×